Denver-based SeaStar designed the SCD for use in patients in the intensive care unit (ICU) with acute or chronic systolic heart failure. These patients have worsening renal function due to cardiorenal syndrome or right ventricular dysfunction. They’re awaiting the implantation of a left ventricular assist device (LVAD).
SeaStar’s SCD halts the downward spiral perpetuated by a hyperinflammatory state, SeaStar chief medical officer Dr. Kevin Chung says.
The company said it expects the breakthrough nod to expedite the clinical development and regulatory review of the SCD.
SeaStar submitted a first-in-human study that saw a patient with severe chronic heart failure treated with the SCD. That patient was ineligible for heart tran…